126 related articles for article (PubMed ID: 38370658)
1. DOT1L stimulates MYC/Mondo transcription factor activity by promoting its degradation cycle on chromatin.
Sepulveda GP; Gushchanskaia ES; Mora-Martin A; Esse R; Nikorich I; Ceballos A; Kwan J; Blum BC; Dholiya P; Emili A; Perissi V; Cardamone MD; Grishok A
bioRxiv; 2024 Feb; ():. PubMed ID: 38370658
[TBL] [Abstract][Full Text] [Related]
2. Silencing or inhibition of H3K79 methyltransferase DOT1L induces cell cycle arrest by epigenetically modulating c-Myc expression in colorectal cancer.
Yang L; Lei Q; Li L; Yang J; Dong Z; Cui H
Clin Epigenetics; 2019 Dec; 11(1):199. PubMed ID: 31888761
[TBL] [Abstract][Full Text] [Related]
3. The Histone Methyltransferase DOT1L Promotes Neuroblastoma by Regulating Gene Transcription.
Wong M; Tee AEL; Milazzo G; Bell JL; Poulos RC; Atmadibrata B; Sun Y; Jing D; Ho N; Ling D; Liu PY; Zhang XD; Hüttelmaier S; Wong JWH; Wang J; Polly P; Perini G; Scarlett CJ; Liu T
Cancer Res; 2017 May; 77(9):2522-2533. PubMed ID: 28209620
[TBL] [Abstract][Full Text] [Related]
4. The proline-rich domain of MML-1 is biologically important but not required for localization to target promoters.
Ceballos A; Esse R; Grishok A
MicroPubl Biol; 2021; 2021():. PubMed ID: 34778725
[TBL] [Abstract][Full Text] [Related]
5. DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells.
Steger DJ; Lefterova MI; Ying L; Stonestrom AJ; Schupp M; Zhuo D; Vakoc AL; Kim JE; Chen J; Lazar MA; Blobel GA; Vakoc CR
Mol Cell Biol; 2008 Apr; 28(8):2825-39. PubMed ID: 18285465
[TBL] [Abstract][Full Text] [Related]
6. DOT1L complex suppresses transcription from enhancer elements and ectopic RNAi in
Esse R; Gushchanskaia ES; Lord A; Grishok A
RNA; 2019 Oct; 25(10):1259-1273. PubMed ID: 31300558
[TBL] [Abstract][Full Text] [Related]
7. A C. elegans Myc-like network cooperates with semaphorin and Wnt signaling pathways to control cell migration.
Pickett CL; Breen KT; Ayer DE
Dev Biol; 2007 Oct; 310(2):226-39. PubMed ID: 17826759
[TBL] [Abstract][Full Text] [Related]
8. The histone methyltransferase DOT1L: regulatory functions and a cancer therapy target.
Wong M; Polly P; Liu T
Am J Cancer Res; 2015; 5(9):2823-37. PubMed ID: 26609488
[TBL] [Abstract][Full Text] [Related]
9. Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer.
Vatapalli R; Sagar V; Rodriguez Y; Zhao JC; Unno K; Pamarthy S; Lysy B; Anker J; Han H; Yoo YA; Truica M; Chalmers ZR; Giles F; Yu J; Chakravarti D; Carneiro B; Abdulkadir SA
Nat Commun; 2020 Aug; 11(1):4153. PubMed ID: 32814769
[TBL] [Abstract][Full Text] [Related]
10. DOT1L cooperates with the c-Myc-p300 complex to epigenetically derepress CDH1 transcription factors in breast cancer progression.
Cho MH; Park JH; Choi HJ; Park MK; Won HY; Park YJ; Lee CH; Oh SH; Song YS; Kim HS; Oh YH; Lee JY; Kong G
Nat Commun; 2015 Jul; 6():7821. PubMed ID: 26199140
[TBL] [Abstract][Full Text] [Related]
11. Chromatin-modifying enzymes as modulators of reprogramming.
Onder TT; Kara N; Cherry A; Sinha AU; Zhu N; Bernt KM; Cahan P; Marcarci BO; Unternaehrer J; Gupta PB; Lander ES; Armstrong SA; Daley GQ
Nature; 2012 Mar; 483(7391):598-602. PubMed ID: 22388813
[TBL] [Abstract][Full Text] [Related]
12. The histone methyltransferase Dot1/DOT1L as a critical regulator of the cell cycle.
Kim W; Choi M; Kim JE
Cell Cycle; 2014; 13(5):726-38. PubMed ID: 24526115
[TBL] [Abstract][Full Text] [Related]
13. Bat3 facilitates H3K79 dimethylation by DOT1L and promotes DNA damage-induced 53BP1 foci at G1/G2 cell-cycle phases.
Wakeman TP; Wang Q; Feng J; Wang XF
EMBO J; 2012 May; 31(9):2169-81. PubMed ID: 22373577
[TBL] [Abstract][Full Text] [Related]
14. The PZP Domain of AF10 Senses Unmodified H3K27 to Regulate DOT1L-Mediated Methylation of H3K79.
Chen S; Yang Z; Wilkinson AW; Deshpande AJ; Sidoli S; Krajewski K; Strahl BD; Garcia BA; Armstrong SA; Patel DJ; Gozani O
Mol Cell; 2015 Oct; 60(2):319-27. PubMed ID: 26439302
[TBL] [Abstract][Full Text] [Related]
15. The upstreams and downstreams of H3K79 methylation by DOT1L.
Vlaming H; van Leeuwen F
Chromosoma; 2016 Sep; 125(4):593-605. PubMed ID: 26728620
[TBL] [Abstract][Full Text] [Related]
16. DOT1L inhibition blocks multiple myeloma cell proliferation by suppressing IRF4-MYC signaling.
Ishiguro K; Kitajima H; Niinuma T; Ishida T; Maruyama R; Ikeda H; Hayashi T; Sasaki H; Wakasugi H; Nishiyama K; Shindo T; Yamamoto E; Kai M; Sasaki Y; Tokino T; Nakase H; Suzuki H
Haematologica; 2019 Jan; 104(1):155-165. PubMed ID: 30171029
[TBL] [Abstract][Full Text] [Related]
17. Deficiency of H3K79 histone methyltransferase Dot1-like protein (DOT1L) inhibits cell proliferation.
Kim W; Kim R; Park G; Park JW; Kim JE
J Biol Chem; 2012 Feb; 287(8):5588-99. PubMed ID: 22190683
[TBL] [Abstract][Full Text] [Related]
18. Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer.
Zhang X; Liu D; Li M; Cao C; Wan D; Xi B; Li W; Tan J; Wang J; Wu Z; Ma D; Gao Q
J Hematol Oncol; 2017 Jan; 10(1):29. PubMed ID: 28114995
[TBL] [Abstract][Full Text] [Related]
19. DOT1L-mediated H3K79 methylation in chromatin is dispensable for Wnt pathway-specific and other intestinal epithelial functions.
Ho LL; Sinha A; Verzi M; Bernt KM; Armstrong SA; Shivdasani RA
Mol Cell Biol; 2013 May; 33(9):1735-45. PubMed ID: 23428873
[TBL] [Abstract][Full Text] [Related]
20. Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancer.
Salvati A; Melone V; Sellitto A; Rizzo F; Tarallo R; Nyman TA; Giurato G; Nassa G; Weisz A
Breast Cancer Res; 2022 Jul; 24(1):52. PubMed ID: 35850772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
